Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.252
Neutral
RSI(14)
44.996
Neutral
STOCH(KDJ)(9,3,3)
48.274
Buy
ATR(14)
0.860
Low Volatility
CCI(14)
-30.838
Neutral
Williams %R
39.353
Buy
TRIX(12,20)
-0.275
Sell
StochRSI(14)
100.000
Buy
Exelixis Inc
EXEL37.880USD
+0.500+1.34%
Close 09/05, 16:00（ET）Quotes delayed by 15 min
10.23BMarket Cap
16.99P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-05Key Insights
The company's fundamentals are relatively very weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
20
analysts
Buy
Current Rating
45.000
Target Price
+18.80%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.61% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 185.97.
Undervalued
The company’s latest PE is 17.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 261.07M shares, decreasing 6.58% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 27.41M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.11.
Financial Health
Currency: USD Updated：2025-09-05The company's current financial score is 6.01, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 555.45M, representing a year-over-year increase of 30.62%, while its net profit experienced a year-over-year increase of 327.73%.
Score
Financials
1.26
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.64
Operational Efficiency
7.28
Growth Potential
6.99
Shareholder Returns
6.85
Company Valuation
Currency: USD Updated：2025-09-05The company’s current valuation score is 3.60, which is higher than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is 17.88, which is 96.80% below the recent high of 35.19 and -12.20% above the recent low of 20.06.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 37/686
No Data
Earnings Forecast
Currency: USD Updated：2025-09-05The company’s current earnings forecast score is 7.60, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Exelixis Inc is 45.00, with a high of 60.00 and a low of 36.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
20
analysts
Buy
Current Rating
45.000
Target Price
+18.80%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
555
Total
5
Median
6
Average
Company name
Ratings
Analysts
Exelixis Inc
EXEL
20
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
27
Ionis Pharmaceuticals Inc
IONS
27
Exact Sciences Corp
EXAS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-05The company’s current price momentum score is 9.31, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 39.68 and the support level at 36.61, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
37.364
Buy
MA10
37.810
Buy
MA20
37.915
Sell
MA50
40.686
Sell
MA100
40.629
Sell
MA200
38.007
Sell
Institutional Confidence
Currency: USD Updated：2025-09-05The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 96.97%, representing a quarter-over-quarter decrease of 1.26%. The largest institutional shareholder is The Vanguard, holding a total of 27.41M shares, representing 10.18% of shares outstanding, with 0.99% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Farallon Capital Management, L.L.C.
State Street Global Advisors (US)
Fuller & Thaler Asset Management Inc.
LSV Asset Management
AQR Capital Management, LLC
Geode Capital Management, L.L.C.
Arrowstreet Capital, Limited Partnership
1
2
Risk Assessment
Currency: USD Updated：2025-09-05The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.91, which is higher than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.36
VaR
+3.04%
240-Day Maximum Drawdown
+21.70%
240-Day Volatility
+45.41%
Return
Best Daily Return
60 days
+7.43%
120 days
+20.84%
5 years
+20.84%
Worst Daily Return
60 days
-16.78%
120 days
-16.78%
5 years
-23.06%
Sharpe Ratio
60 days
-0.84
120 days
+0.37
5 years
+0.58
Risk Assessment
Maximum Drawdown
240 days
+21.70%
3 years
+21.70%
5 years
+41.47%
Return-to-Drawdown Ratio
240 days
+1.90
3 years
+2.07
5 years
+0.51
Skewness
240 days
+1.00
3 years
+0.88
5 years
-0.60
Volatility
Realised Volatility
240 days
+45.41%
5 years
+37.72%
Standardised True Range
240 days
+3.15%
5 years
+1.90%
Downside Risk-Adjusted Return
120 days
+49.05%
240 days
+49.05%
Maximum Daily Upside Volatility
60 days
+59.19%
Maximum Daily Downside Volatility
60 days
+41.15%
Liquidity
Average Turnover Rate
60 days
+1.20%
120 days
+1.15%
5 years
--
Turnover Deviation
20 days
+11.42%
60 days
+42.86%
120 days
+36.45%
Peer Comparison
Currency: USD Updated：2025-09-05Exelixis Inc
EXEL
6.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
7.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
7.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
